Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 9/20 | 0.83 |
| ▸ | STK3 | Q13188 | 9/20 | 0.80 |
| ▸ | EGFR | P00533 | 9/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.78 |
| ▸ | BTK | Q06187 | 2/20 | 0.71 |
| ▸ | STK25 | O00506 | 1/20 | 0.71 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.71 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.71 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.71 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.71 |
| ▸ | STK17B | O94768 | 1/20 | 0.71 |
| ▸ | STK10 | O94804 | 1/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.71 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362770 | 1.00 | STK4 (0.83) | STK4STK3EGFRERBB2BTK | |
| SCHEMBL19480018 | 0.93 | STK4 (0.73) | STK4STK3EGFRERBB2BTK | |
| SCHEMBL10080596 | 0.93 | STK4 (0.76) | STK4STK3EGFRERBB2BTK | |
| SCHEMBL22419770 | 0.91 | STK4 (1.00) | STK4STK3EGFRERBB2BTK | |
| SCHEMBL22419640 | 0.91 | STK4 (0.90) | STK4STK3EGFRERBB2BTK | |
| SCHEMBL11941924 | 0.90 | STK4 (0.67) | STK4STK3EGFRERBB2BTK | |
| SCHEMBL3476976 | 0.89 | STK4 (0.88) | STK4STK3EGFRERBB2BTK | |
| SCHEMBL2384641 | 0.89 | STK3 (1.00) | STK4STK3EGFRERBB2BTK | |
| SCHEMBL33532011 | 0.89 | STK3 (1.00) | STK4STK3EGFRERBB2BTK | |
| SCHEMBL22419782 | 0.89 | STK3 (1.00) | STK4STK3EGFRERBB2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303523-A1 | METHOD FOR PREPARING PYROTINIB | SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303523-A1 | METHOD FOR PREPARING PYROTINIB | SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD (CN) | 2023-09-28 | — | — | US | disclosed |
| CN-115974842-A | Preparation method of pyrroltinib | 苏州宝圣医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2022088573-A1 | METHOD FOR PREPARING PYROTINIB | 苏州富士莱医药股份有限公司 | 2022-05-05 | — | — | WO | disclosed |
| EP-2479174-B1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-10-18 | — | — | EP | disclosed |
| EP-2479174-B1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-10-18 | — | — | EP | disclosed |
| EP-2684877-B1 | PHARMACEUTICALLY ACCEPTABLE SALT OF (E)-N-[4-[[3-CHLORO-4-(2-PYRIDYLMETHOXY)PHENYL]AMINO]-3-CYANO-7-ETHOXY-6-QUINOLYL]-3-[(2R)-1-METHYLPYRROLIDIN-2-YL]PROP-2-ENAMIDE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2016-10-19 | — | — | EP | disclosed |
| EP-2684877-B1 | PHARMACEUTICALLY ACCEPTABLE SALT OF (E)-N-[4-[[3-CHLORO-4-(2-PYRIDYLMETHOXY)PHENYL]AMINO]-3-CYANO-7-ETHOXY-6-QUINOLYL]-3-[(2R)-1-METHYLPYRROLIDIN-2-YL]PROP-2-ENAMIDE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2016-10-19 | — | — | EP | disclosed |
| US-9358227-B2 | Pharmaceutical uses of 6-amino quinazoline or 3-cyano quinoline derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9358227-B2 | Pharmaceutical uses of 6-amino quinazoline or 3-cyano quinoline derivatives | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-20150126550-A1 | PHARMACEUTICAL USES OF 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2015-05-07 | — | — | US | disclosed |
| US-8901140-B2 | 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-12-02 | — | — | US | disclosed |
| US-8901140-B2 | 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2014-12-02 | — | — | US | disclosed |
| EP-2684877-A2 | PHARMACEUTICALLY ACCEPTABLE SALT OF (E)-N-[4-[[3-CHLORO-4-(2-PYRIDYLMETHOXY)PHENYL]AMINO]-3-CYANO-7-ETHOXY-6-QUINOLYL]-3-[(2R)-1-METHYLPYRROLIDIN-2-YL]PROP-2-ENAMIDE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2014-01-15 | — | — | EP | disclosed |
| EP-2684877-A2 | PHARMACEUTICALLY ACCEPTABLE SALT OF (E)-N-[4-[[3-CHLORO-4-(2-PYRIDYLMETHOXY)PHENYL]AMINO]-3-CYANO-7-ETHOXY-6-QUINOLYL]-3-[(2R)-1-METHYLPYRROLIDIN-2-YL]PROP-2-ENAMIDE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2014-01-15 | — | — | EP | disclosed |
| US-20130338190-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF (E)-N-[4-[[3-CHLORO-4-(2-PYRIDYLMETHOXY)PHENYL]AMINO]-3-CYANO-7-ETHOXY-6-QUINOLYL]-3-[(2R)-1-METHYLPYRROLIDIN-2-YL]PROP-2-ENAMIDE, PREPARATION METHOD THEREOF, AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2013-12-19 | — | — | US | disclosed |
| EP-2479174-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-07-25 | — | — | EP | disclosed |
| EP-2479174-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-07-25 | — | — | EP | disclosed |
| US-20120165352-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165352-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338190-A1 | PHARMACEUTICALLY ACCEPTABLE SALT OF (E)-N-[4-[[3-CHLORO-4-(2-PYRIDYLMETHOXY)PHENYL]AMINO]-3-CYANO-7-ETHOXY-6-QUINOLYL]-3-[(2R)-1-METHYLPYRROLIDIN-2-YL]PROP-2-ENAMIDE, PREPARATION METHOD THEREOF, AND MEDICAL USE THEREOF | CSNK1A1L, CSNK1A1, CSNK1E | STK4 275/4885STK3 432/4885EGFR 204/4885 |
| US-20230303523-A1 | METHOD FOR PREPARING PYROTINIB | JAK2, SRMS, JAK1 | STK4 1025/4885STK3 1563/4885EGFR 934/4885 |
| US-20120165352-A1 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | CSNK1G3, CSNK1A1, CSNK1A1L | STK4 179/4885STK3 41/4885EGFR 3299/4885 |
| US-20150126550-A1 | PHARMACEUTICAL USES OF 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES | PYGL, CSNK1G3, G6PD | STK4 169/4885STK3 32/4885EGFR 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.